Combination Therapy for Patients with Choroidal Neovascularization (CNV)

MEEI Protocol ID 09-10-101
National Clinical Trial (NCT) Number NCT01256580
Choroidal Neovascularization (CNV) due to causes other than Age-Related Macular Degeneration
Massachusetts Eye and Ear Infirmary
Principal Investigator
Ivana Kim, M.D.
Study Design
This is a Phase I single center, unmasked, randomized clinical trial
Study Objective
To compare the efficacy of Avastin alone to combination therapy with Avastin, photodynamic therapy (PDT), and dexamethasone for patients with choroidal neovascularization (CNV) secondary to causes other than age-related macular degeneration. These medications have anti-angiogenic and anti-inflammatory properties which may reduce or prevent the vision loss associated with the development of CNV. Combination therapy may enhance the beneficial effect of these drugs.
Who is Eligible
Individuals, at least 18 years of age, with a clinical diagnosis of choroidal neovascularization secondary to any cause other than age-related macular degeneration. Previous treatment with photodynamic therapy, laser photocoagulation, intraocular steroids, or other anti-angiogenic compounds is allowed but must have been performed more than 30 days before entering the study.
Subject Enrollment
We are currently enrolling individuals with CNV who meet all study criteria.
Study Procedures
Qualified patients will be randomly assigned to receive intravitreal injections of Avastin or combination therapy for a period of 12 months. Patients will be followed monthly throughout the study period to determine the need for treatment.
For More Information
Jacqueline Sullivan, Study Coordinator



Click here to return to the Ophthalmology Clinical Research page.